In another study lasting over 52 weeks and involving more than 800 models, the peptide potentially led to a mean reduction in visceral adiposity by -17.5%
48 HiroseM.TozawaK.OkadaA.HamamotoS.HigashibataY.GaoB.et al
Clarify whether OS is the initial factor driving the occurrence of the disease, a synergistic factor that accompanies and amplifies hormonal effects, or a metabolic result after abnormal cell proliferation
Take control of your energy, metabolism, and overall health today
It is a research compound and is not FDA-approved
On the other hand, IGF-1 LR3 may also demonstrate anti-inflammatory properties and regeneration of cells, tissues, and skeletal health structures in experimental organisms during clinical trials